Skip to Main Content
Ned Milenkovich Bio Image | Much Law

Chair of the firm's Health Care practice and a registered pharmacist, Ned helps drug, pharmacy, and other health care clients meet the demands of federal and state regulators, strengthen their positions in a highly competitive marketplace, and resolve a broad range of commercial disputes. Ned represents businesses of all sizes, with a focus on companies with interests and operations throughout the drug supply chain.

Ned has extensive experience in medical device, drug, and pharmacy law. He advises clients on regulatory compliance, including matters involving requirements of the U.S. Food and Drug Administration, the Drug Enforcement Administration, Medicare Part D matters, 340B issues, Health Insurance Portability and Accountability Act compliance, prescription drug monitoring programs, drug diversion issues, and drug pedigree and compounding issues. He also advises on a broad range of licensing, transactional, and corporate compliance and accountability issues. 

Ned's clients include drug manufacturers, wholesale distributors, third-party logistics providers, pharmacy technology companies, prescription management companies, physician practices, and pharmacy retailers, including brick-and-mortar, long-term care, mail-order, and specialty pharmacies.

A longtime thought leader in the drug and pharmacy industry, Ned is a member of the editorial advisory board of Pharmacy Times, where he helps guide the editorial direction and contributes content to its print, digital, and live events channels.

Ned regularly attends and speaks at events organized by leading legal and industry groups, such as Asembia, the National Association of Chain Drug Stores, and the Chain Drug Consortium.

Much More Than My Work

After relocating to Naples, I discovered a passion for cooking and preparing food in new ways, bicycling, and enjoying the outdoors. I also enjoy being near the beach with my family and friends, as well as discovering remote and quaint places in Florida.

News & Insights

much more